164 related articles for article (PubMed ID: 36623227)
21. Innovative financing instruments for global health 2002-15: a systematic analysis.
Atun R; Silva S; Knaul FM
Lancet Glob Health; 2017 Jul; 5(7):e720-e726. PubMed ID: 28619230
[TBL] [Abstract][Full Text] [Related]
22. Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000-17: a financial modelling study.
Su Y; Garcia Baena I; Harle AC; Crosby SW; Micah AE; Siroka A; Sahu M; Tsakalos G; Murray CJL; Floyd K; Dieleman JL
Lancet Infect Dis; 2020 Aug; 20(8):929-942. PubMed ID: 32334658
[TBL] [Abstract][Full Text] [Related]
23. Tracking government spending on immunization: The joint reporting forms, national health accounts, comprehensive multi-year plans and co-financing data.
Ikilezi G; Bachmeier SD; Cogswell IE; Maddison ER; Stutzman HN; Tsakalos G; Brenzel L; Dieleman JL; Micah AE
Vaccine; 2021 Jun; 39(25):3410-3418. PubMed ID: 34020816
[TBL] [Abstract][Full Text] [Related]
24. Vaccine financing in the Middle East and Africa: An overview from 2010 to 2019.
Catharina de Beer J; Goto D; Miller-Janson H; Holl R; Bencina G
Vaccine; 2022 Sep; 40(39):5691-5700. PubMed ID: 36030126
[TBL] [Abstract][Full Text] [Related]
25. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
Le Gargasson JB; Breugelmans JG; Mibulumukini B; Da Silva A; Colombini A
Vaccine; 2013 Apr; 31(15):1886-91. PubMed ID: 23462529
[TBL] [Abstract][Full Text] [Related]
26. Potential for additional government spending on HIV/AIDS in 137 low-income and middle-income countries: an economic modelling study.
Haakenstad A; Moses MW; Tao T; Tsakalos G; Zlavog B; Kates J; Wexler A; Murray CJL; Dieleman JL
Lancet HIV; 2019 Jun; 6(6):e382-e395. PubMed ID: 31036482
[TBL] [Abstract][Full Text] [Related]
27. Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries.
Saxenian H; Hecht R; Kaddar M; Schmitt S; Ryckman T; Cornejo S
Health Policy Plan; 2015 Mar; 30(2):197-205. PubMed ID: 24510369
[TBL] [Abstract][Full Text] [Related]
28. Landscaping analysis of immunization progress and program structures in selected middle income Southeast Asian countries.
Basa JE; Clemens R; Clemens SAC; Nicholson M
Vaccine; 2024 Apr; 42(9):2326-2336. PubMed ID: 38448324
[TBL] [Abstract][Full Text] [Related]
29. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
Ngabo F; Levin A; Wang SA; Gatera M; Rugambwa C; Kayonga C; Donnen P; Lepage P; Hutubessy R
Vaccine; 2015 Dec; 33(51):7357-7363. PubMed ID: 26519548
[TBL] [Abstract][Full Text] [Related]
30. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM; Gleizes O; Covilard JP
Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
[TBL] [Abstract][Full Text] [Related]
31. Tracking development assistance and government health expenditures for 35 malaria-eliminating countries: 1990-2017.
Shretta R; Zelman B; Birger ML; Haakenstad A; Singh L; Liu Y; Dieleman J
Malar J; 2017 Jul; 16(1):251. PubMed ID: 28705160
[TBL] [Abstract][Full Text] [Related]
32. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
Lydon P; Levine R; Makinen M; Brenzel L; Mitchell V; Milstien JB; Kamara L; Landry S
Vaccine; 2008 Dec; 26(51):6706-16. PubMed ID: 18952134
[TBL] [Abstract][Full Text] [Related]
33. EPIC Studies: Governments Finance, On Average, More Than 50 Percent Of Immunization Expenses, 2010-11.
Brenzel L; Schütte C; Goguadze K; Valdez W; Le Gargasson JB; Guthrie T
Health Aff (Millwood); 2016 Feb; 35(2):259-65. PubMed ID: 26858378
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 Vaccination in Lower-Middle Income Countries: National Stakeholder Views on Challenges, Barriers, and Potential Solutions.
Tagoe ET; Sheikh N; Morton A; Nonvignon J; Sarker AR; Williams L; Megiddo I
Front Public Health; 2021; 9():709127. PubMed ID: 34422750
[TBL] [Abstract][Full Text] [Related]
35. Immunization funding across 28 European countries.
Faivre P; Benčina G; Campbell R; Quilici S; Dauby N; Tešović G; Bonanni P; Drury R
Expert Rev Vaccines; 2021 Jun; 20(6):639-647. PubMed ID: 33759675
[TBL] [Abstract][Full Text] [Related]
36. Challenges to sustainable immunization systems in Gavi transitioning countries.
Cernuschi T; Gaglione S; Bozzani F
Vaccine; 2018 Oct; 36(45):6858-6866. PubMed ID: 30268735
[TBL] [Abstract][Full Text] [Related]
37. GAVI and the Vaccine Fund--a boon for immunization in the developing world.
Balaji KA
Indian J Public Health; 2004; 48(2):45-8. PubMed ID: 15709583
[TBL] [Abstract][Full Text] [Related]
38. Status of New Vaccine Introduction - Worldwide, September 2016.
Loharikar A; Dumolard L; Chu S; Hyde T; Goodman T; Mantel C
MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(41):1136-1140. PubMed ID: 27764083
[TBL] [Abstract][Full Text] [Related]
39. Public financing of health in developing countries: a cross-national systematic analysis.
Lu C; Schneider MT; Gubbins P; Leach-Kemon K; Jamison D; Murray CJ
Lancet; 2010 Apr; 375(9723):1375-87. PubMed ID: 20381856
[TBL] [Abstract][Full Text] [Related]
40. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3.
Global Burden of Disease Health Financing Collaborator Network
Lancet; 2020 5-11 Sep; 396(10252):693-724. PubMed ID: 32334655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
